South Korean health authorities have expanded eligibility for oral COVID-19 antiviral drugs.
The Central Disaster Management Headquarters says that, from Monday, Pfizer's Paxlovid will be used for adults or children 12 years or older with a high risk of developing a severe case due to factors, such as underlying diseases.
It added Lagevrio, the second oral pill approved to treat COVID-19 patients in Korea, will be used for adults with underlying medical conditions.
Previously, these drugs were only given to senior citizens over 60, or those over 40 with underlying illnesses.
00:43
Global credit appraiser S&P Global Ratings forecasts 5% inflation for S. Korea this year
03:42
08:04
00:43
01:56
02:35
